Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AZN: AstraZeneca PLC -- Ignore unavailable to you. Want to Upgrade?

To: Bill Habeck who wrote (7)	6/5/2002 9:54:58 AM
From: EdR	Respond to of 35

Hi Bill, Thanks for the 'heads-up' on the latest with Crestor. The news sure sounds good. The market doesn't seem to think it's big news for the stock. I've been watching it slide down for a while looking for a buy spot which I think is right around here. I hear that the Iressa cancer drug is right on track and could be approved within 6 to 12 months. Regards, Ed...

To: Bill Habeck who wrote (7)	7/6/2002 10:37:42 AM
From: EdR	Read Replies (1) \| Respond to of 35

Bill, The following is from an article in today's NYT Web edition. Regards, Ed... <snip> <<AstraZeneca Scores Coup as Cancer Drug Gains in Japan By ANDREW POLLACK AstraZeneca said yesterday that its new cancer drug, Iressa, had been approved to treat lung cancer in Japan, making it the first of a new class of cancer medicines to reach the market anywhere, beating Erbitux from ImClone Systems. >> <snip>